Anyhow, performing adequate corrections to the statistical model, we demonstrated that younger age was still significantly associated with a lower chance to achieve a satisfactory response to first-line SRL treatment, while higher IGF-1 xULN at diagnosis and T2-hypointense signal of the tumor both maintained a trend towards a higher chance to have a better response. The gene discussed is IGF1; the disease is neoplasm.